leisure time -WSS

leisure time

author：fashion 2025-09-06 04:38:12 - browse：54

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Neurocrine congenital adrenal hyperplasia trial succeeds

WSS

People with substance use disorder deserve online privacy

How the messy conversation about Dolly changed bioethics

Cano Health’s bankruptcy is a warning for Medicare Advantage

PBMs drew scrutiny in House hearing — and so did pharma

The Biogen Aduhelm mess could happen again

Problems with a popular proposal to regulate AI in health care

Wikipedia

leisure time

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Chamber of Commerce, DOJ clash in court over drug prices

In age of alternative facts, a scholarly course on calling out crap

House panel takes first step toward fixing drug shortages

Sports medicine is finally prioritizing gender equality

Gene therapy for Afghan refugees’ infant will be fully covered

Drug repurposing or repositioning? The language matters

Global cancer cases to surge 77% by 2050, WHO report says

Duchenne breakthrough therapy leaves behind pioneering families

FDA panel to weigh safety of artificial wombs for preterm births

Wikipedia

How the messy conversation about Dolly changed bioethics

Fed up with FDA, ALS advocates consider a take

David Liu startup to focus on CRISPR delivery

Why the quest to eradicate polio has stumbled

FDA panel to weigh safety of artificial wombs for preterm births

A protest over insulin prices is seen as a fight for life

leisure time

entertainment

explore

focus